Your browser is no longer supported. Please, upgrade your browser.
MannKind Corporation
Index- P/E- EPS (ttm)-0.26 Insider Own0.50% Shs Outstand249.07M Perf Week-1.42%
Market Cap1.07B Forward P/E- EPS next Y-0.08 Insider Trans3.99% Shs Float236.42M Perf Month7.18%
Income-57.20M PEG- EPS next Q-0.04 Inst Own30.70% Short Float16.33% Perf Quarter23.67%
Sales65.10M P/S16.45 EPS this Y3.10% Inst Trans7.65% Short Ratio6.23 Perf Half Y117.71%
Book/sh-0.81 P/B- EPS next Y42.90% ROA-59.10% Target Price6.50 Perf Year242.62%
Cash/sh0.26 P/C15.99 EPS next 5Y35.60% ROE30.70% 52W Range1.14 - 6.25 Perf YTD33.55%
Dividend- P/FCF- EPS past 5Y43.70% ROI82.50% 52W High-32.91% Beta1.87
Dividend %- Quick Ratio1.00 Sales past 5Y- Gross Margin62.90% 52W Low267.80% ATR0.27
Employees241 Current Ratio1.10 Sales Q/Q15.00% Oper. Margin-74.00% RSI (14)52.03 Volatility6.73% 7.50%
OptionableYes Debt/Eq- EPS Q/Q-72.20% Profit Margin-87.90% Rel Volume0.32 Prev Close4.18
ShortableYes LT Debt/Eq- EarningsFeb 25 BMO Payout- Avg Volume6.20M Price4.19
Recom1.40 SMA206.10% SMA50-4.56% SMA20045.74% Volume1,568,861 Change0.31%
Dec-24-19Initiated Oppenheimer Outperform $2.50
Oct-25-19Initiated Cantor Fitzgerald Overweight $3
May-14-19Initiated BTIG Research Buy $3
Mar-04-19Initiated SVB Leerink Outperform $3
Feb-22-19Initiated SVB Leerink Outperform $3
Feb-28-18Downgrade Maxim Group Hold → Sell $1
Nov-01-17Downgrade Maxim Group Buy → Hold
Oct-10-17Initiated H.C. Wainwright Buy $7
Oct-06-17Reiterated Maxim Group Buy $4 → $7
Aug-11-17Initiated Maxim Group Buy $4
May-10-16Reiterated RBC Capital Mkts Underperform $0.15 → $0.20
May-10-16Reiterated Piper Jaffray Underweight $0.05 → $0.10
Jan-06-16Reiterated RBC Capital Mkts Underperform $1 → $0.15
Jan-06-16Reiterated Piper Jaffray Underweight $1.50 → $0.05
Nov-04-15Downgrade RBC Capital Mkts Outperform → Underperform $9 → $1
Sep-09-15Downgrade Piper Jaffray Neutral → Underweight
Aug-03-15Reiterated RBC Capital Mkts Outperform $10 → $9
May-11-15Reiterated MLV & Co Hold $7 → $4
May-11-15Downgrade JP Morgan Neutral → Underweight
Apr-16-15Reiterated RBC Capital Mkts Outperform $13 → $10
Apr-19-21 06:00AM  
Mar-16-21 09:00AM  
Mar-15-21 08:00AM  
Mar-10-21 05:00PM  
Mar-02-21 05:00PM  
Mar-01-21 07:00AM  
Feb-26-21 10:05AM  
Feb-25-21 08:00AM  
Feb-24-21 02:57PM  
Feb-18-21 05:00PM  
Feb-04-21 08:33PM  
Jan-04-21 05:00PM  
Dec-29-20 08:53AM  
Dec-18-20 07:45AM  
Dec-17-20 04:44PM  
Dec-10-20 08:00AM  
Dec-07-20 11:33PM  
Dec-01-20 08:00AM  
Nov-30-20 08:00AM  
Nov-20-20 07:37AM  
Nov-19-20 05:00PM  
Nov-10-20 10:15AM  
Nov-08-20 09:37AM  
Nov-06-20 08:44PM  
Nov-04-20 05:15PM  
Oct-29-20 08:00AM  
Oct-28-20 12:32PM  
Oct-23-20 10:38AM  
Sep-08-20 08:00AM  
Aug-31-20 09:00AM  
Aug-24-20 02:28PM  
Aug-20-20 08:39AM  
Aug-07-20 05:00PM  
Aug-05-20 06:35PM  
Jul-29-20 05:00PM  
Jul-20-20 09:00AM  
Jun-22-20 08:30AM  
Jun-18-20 08:49AM  
Jun-17-20 05:00PM  
Jun-15-20 04:07PM  
Jun-13-20 12:00PM  
Jun-05-20 01:10PM  
May-25-20 11:12AM  
May-19-20 08:44PM  
May-07-20 04:36AM  
May-06-20 05:15PM  
Apr-29-20 05:00PM  
Apr-28-20 12:33PM  
Apr-15-20 08:00AM  
Mar-31-20 10:54AM  
Mar-24-20 09:00AM  
Mar-17-20 09:00AM  
Mar-07-20 03:31AM  
Feb-25-20 08:00AM  
Feb-24-20 06:25PM  
Feb-20-20 09:00AM  
Feb-18-20 09:00AM  
Jan-22-20 09:22AM  
Jan-20-20 04:37AM  
Jan-10-20 05:00AM  
Jan-06-20 08:00AM  
Dec-20-19 06:21PM  
Nov-29-19 09:00AM  
Nov-21-19 09:00AM  
Nov-16-19 09:39PM  
Nov-12-19 02:26PM  
Nov-06-19 08:00AM  
Nov-04-19 09:00AM  
Oct-30-19 09:00AM  
Sep-26-19 09:00AM  
Sep-19-19 09:00AM  
Sep-12-19 11:25AM  
Sep-10-19 03:30PM  
Aug-30-19 09:00AM  
Aug-23-19 12:00PM  
Aug-16-19 08:35AM  
Aug-08-19 11:23AM  
Aug-07-19 04:01PM  
Aug-05-19 09:00AM  
Aug-01-19 05:02PM  
Jul-31-19 09:00AM  
Jul-18-19 08:52AM  
Jul-15-19 09:00AM  
Jul-11-19 04:14PM  
Jul-09-19 12:09PM  
Jun-14-19 10:00AM  
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Castagna MichaelChief Executive OfficerMar 05Buy3.383,00010,1403,000Mar 08 05:00 PM
Castagna MichaelChief Executive OfficerJan 31Buy1.335,0006,6501,117,560Feb 02 06:18 PM
Tross Stuart AChief People & Workpl OfficerJan 31Buy1.335,0006,650481,991Feb 02 06:18 PM
Binder Steven B.Chief Financial OfficerJan 31Buy1.331,5572,071398,822Feb 02 06:18 PM
Binder Steven B.Chief Financial OfficerJul 31Buy1.251,5221,90233,265Aug 04 06:45 PM
Tross Stuart AChief People & Workpl OfficerJul 31Buy1.255,0006,250114,720Aug 04 06:41 PM
Kendall David MChief Medical OfficerJul 31Buy1.254,0415,05141,059Aug 04 06:39 PM
Castagna MichaelChief Executive OfficerJul 31Buy1.255,0006,250203,560Aug 04 06:38 PM
Castagna MichaelChief Executive OfficerJun 15Buy1.4110,36314,63810,000Jun 16 05:36 PM
Castagna MichaelChief Executive OfficerJun 15Buy1.4930,00044,700198,560Jun 16 05:36 PM
Castagna MichaelChief Executive OfficerJun 12Buy1.41689668Jun 16 05:36 PM